Needham analyst David Saxon reiterated a Buy rating on SI-Bone today and set a price target of $24.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
David Saxon has given his Buy rating due to a combination of factors that highlight SI-Bone’s strong financial performance and future potential. The company’s revenue for the third quarter of 2025 exceeded expectations, and management has subsequently increased their revenue guidance for the year. This indicates a positive outlook and confidence in continued growth.
Additionally, Saxon notes that the guidance appears conservative, particularly as the fourth quarter is expected to show the smallest increase in sales. However, management is optimistic about 2026, citing potential benefits from new product launches and favorable reimbursement conditions. These factors suggest that there is room for further revenue and earnings growth, supporting the Buy rating.
According to TipRanks, Saxon is an analyst with an average return of -0.1% and a 36.72% success rate. Saxon covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, DENTSPLY SIRONA, and Sight Sciences.